Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Abstract

Eosinophilia is associated with worsening asthma severity and decreased lung function, with increased exacerbation frequency. We assessed the safety and efficacy of benralizumab, a monoclonal antibody against interleukin-5 receptor α that depletes eosinophils by antibody-dependent cell-mediated cytotoxicity, for patients with severe, uncontrolled asthma with eosinophilia.

Journal

Title: The Lancet

Abbreviated Title: The Lancet

Publisher: Elsevier BV

ISSN (Print): 01406736

Publication date Created: October 2016

Publication date (Print): October 2016

Volume: 388

Issue: 10056

Pages: 2115-2127

Article

DOI: 10.1016/S0140-6736(16)31324-1

PubMed ID: 27609408

Copyright statement: © 2016

License:

http://www.elsevier.com/tdm/userlicense/1.0/

Product

Self URI (article page): http://linkinghub.elsevier.com/retrieve/pii/S0140673616313241